ClinicalTrials.gg
RecruitingNCT07391852CLEARUpdated Oct 14, 2026

Circadian Light Exposure Adjustment for Restfulness

An interventional study of Amber Tinted Glasses and Clear Glasses in Sleep Onset Latency, sponsored by University of Arizona. Recruiting at 1 site in United States. Open to participants aged 60 Months to 83 Months. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of Arizona · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Months to 83 Months
Sex
All
01

Study summary

Many young children are exposed to light int he evening hours before bedtime. Children's biological clocks are highly sensitive to evening light exposure, which can delay the timing of the clock and make it harder to fall asleep. The purpose of this study is to test three strategies (adjustment to home lighting, amber-tinted glasses, clear glasses) to reduce evening light exposure in children ages 5-6 years with parent-reported sleep onset difficulties in order to improve their sleep and the timing of their biological clock. This study takes place over approximately 5 weeks. After baseline assessments of children's sleep timing, light exposure, cognition, and circadian rhythms, they will be randomly assigned to one of three interventions to reduce evening light exposure for two weeks. After the two-week intervention period, the baseline measures are repeated and parents are interviewed about their and their child's experiences with the intervention.

Read the detailed description

Evening sleep difficulties are common in young children and can contribute to behavioral and health problems. Sleep timing is regulated in part by the circadian clock, which is highly sensitive to light exposure. Light in the hour before bedtime can suppress melatonin, delay circadian timing, and make it harder for children to fall asleep. Despite evidence of high circadian sensitivity to evening light, few studies have tested interventions to improve sleep timing in early childhood using light-based strategies.

This study evaluates the feasibility, acceptability, and preliminary efficacy of two light-mitigation strategies to advance sleep and circadian timing in children aged 5 to 6 years with parent-reported sleep onset difficulties. Children will participate in a five-week study consisting of baseline assessments, a two-week intervention period, and post-intervention assessments. Parents of enrolled children will provide written informed consent for their child's participation. Children are under age 7 years and are not required to provide formal assent.

Baseline assessments will include sleep timing, duration, and quality measured via actigraphy, circadian phase assessed with salivary dim-light melatonin onset (DLMO), parent-reported sleep behaviors, and a cognitive battery. Children will then be randomly assigned to one of three interventions: (1) smart home lighting to reduce evening short-wavelength light, (2) amber-tinted glasses worn in the hour before bedtime, or (3) clear glasses as a sham control. Interventions will last two weeks, with adherence monitored throughout.

After the intervention, all assessments will be repeated, and parents will participate in structured interviews to report on the feasibility and acceptability of the assigned strategy. Exploratory measures will include baseline pupillary light response to examine individual differences in photosensitivity as potential moderators of intervention effects.

Data from this study will inform the feasibility and acceptability of light-based interventions in young children (Aim 1), provide preliminary evidence of effects on sleep and circadian timing (Aim 2), and explore whether photosensitivity moderates response to the interventions (Exploratory Aim 3).

02

Conditions studied

  • Sleep Onset Latency

Keywords

  • Behavioral sleep problems
  • Circadian phase
  • sleep onset latency
  • Early childhood
  • dim light melatonin onset (DLMO)
  • Evening light exposure
  • Light intervention
03

In context

Lead sponsor

University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Months to 83 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion requires that children are aged 5.0-6.9 years at the time of enrollment with a parent-reported sleep onset of ≥ 60 min after parents' desired bedtime at least three nights per week.

One adult parent of each participating child will also take part in the study. Parents must be able to provide consent for themselves and their child and to complete the interview at the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Children are excluded for the following reasons:

    • All sleep disorders as indicated on the telephone screener or by clinical cut-off scores on the Children's Sleep Habits Questionnaire (CSHQ), except for insomnia or DSWPD as features of these disorders are directly targeted by the intervention. Secondary analyses will explore if outcomes differ among participants with or without parent-reported symptoms consistent with these diagnoses.
    • Physical abilities that interfere with assessments (e.g., visual impairment), developmental disabilities (e.g., autism, attention-deficit/hyperactivity disorder (ADHD), pervasive developmental disorder), epilepsy or other neurological disorders, metabolic disorders, medical conditions that commonly require treatments or assessments during the night (e.g., cancer, diabetes, active asthma), current infection or lead poisoning; a head injury involving loss of consciousness in the past 6 months.
    • Current use of medications affecting daytime sleepiness, the circadian system, or light sensitivity.
    • Eye disorders or color blindness (determined with Ishihara Color Vision Test); corrected vision with eyeglasses is permitted.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Amber Tinted Glasses

    Wearing "blue-blocker" glasses (lenses that filter out the blue portion of the visible spectrum) can reduce the melatonin suppression and alertness effects of evening light exposure in both adults and adolescents, as well as advance the timing of the circadian clock and sleep onset, compared with participants wearing placebo lenses. This intervention will examine their efficacy in advancing young children's sleep and circadian timing. Children will be given a pair of glasses (Block Blue Light), with amber-tinted lenses (advertised as blocking 100% of light from 380-550 nm. Children will wear the glasses starting 1 h before parent's selected bedtime each evening across the two-week intervention. Parents will also complete a daily diary detailing when the glasses are worn.

    Device: Amber Tinted Glasses

  • Sham comparator
    Clear Glasses

    The sham comparator consists of the same protocols for the amber-tinted glasses, except that children will wear a pair of glasses with clear lenses (advertised as blocking 50% of light from 400-500 nm), which are significantly less effective at blocking short-wavelength light.

    Device: Clear Glasses

  • Experimental
    Smart Lightbulbs

    The presence of more blue light in the home is associated with later circadian timing in both school-aged children and adults. This intervention will adjust the evening home lighting environment to be less stimulating to children's circadian clocks. Smart light bulbs (dimmable and color tunable LED bulbs) will be installed in participants' homes light fixtures, or in the child's bedroom, bathroom, as well as areas the child is likely to spend time in after dinner (i.e., living room, playroom). The researchers will program the lights to transition to a lower CCT and dimmer intensity to achieve the recommended evening mEDI of 10 lux starting 1 h before the child's parent-selected bedtime.

    Device: Smart Lightbulbs

Interventions

  • DeviceAmber Tinted Glasses

    Children will wear amber-tinted glasses in the evening hours before bedtime to reduce exposure to short-wavelength (blue) light. The glasses are intended to reduce circadian disruption associated with evening light exposure.

  • DeviceClear Glasses

    Children will wear clear glasses in the evening hours before bedtime. This sham intervention controls for wearing glasses without reducing light exposure.

  • DeviceSmart Lightbulbs

    Smart light bulbs will be installed in the child's home and programmed to reduce short-wavelength light exposure during evening hours before bedtime.

06

What researchers measure

Primary outcomes

  1. Intervention Feasibility

    Feasibility will be assessed using adherence/compliance rates to assigned intervention protocols.

    Time frame: Throughout the two-week intervention period.

  2. Acceptability

    Acceptability will be assessed using parent-reported qualitative interviews conducted post-intervention.

    Time frame: Week 5

Secondary outcomes

  1. Circadian Timing

    Dim light melatonin onset, a measure of circadian timing, will be assessed via saliva samples.

    Time frame: Assessed once in Week 2 and once in Week 5

  2. Sleep Timing

    Throughout the duration of the study, the child will wear a wrist actigraph which records sleep timing and light exposure. The actigraph is a watch-size monitor worn on the non-dominant wrist, providing continuous imputation of sleep-wake states via arm activity. These data will be used to examine changes in habitual sleep timing, sleep onset latency.

    Time frame: Throughout the 5 week protocol

  3. Light Exposure

    Measured by the wrist-worn actigraph watch in 1-min epochs throughout data collection. These data provide an objective measure of the child's light exposure throughout the protocol (including compliance with the home lighting intervention) and will be used to examine changes in habitual light exposure.

    Time frame: Throughout the 5 week protocol.

  4. Sleep-Related Behaviors

    Change in parent-reported sleep behaviors assessed via validated questionnaires.

    Time frame: Assessed once in Week 1 and once in Week 5

Other outcomes

  1. Pupillary Light Response

    Baseline pupillary light response will be assessed as a measure of individual differences in photosensitivity.

    Time frame: Baseline

  2. Cognitive Functioning

    Change in cognitive performance from pre- to post-intervention assessed using a standardized cognitive battery (NIH Toolbox).

    Time frame: Assessed once in Week 1 and once in Week 5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Werner H, Lebourgeois MK, Geiger A, Jenni OG. Assessment of chronotype in four- to eleven-year-old children: reliability and validity of the Children's Chronotype Questionnaire (CCTQ). Chronobiol Int. 2009 Jul;26(5):992-1014. doi: 10.1080/07420520903044505. PubMed 19637055 ↗
  • LeBourgeois MK, Harsh JR. Development and psychometric evaluation of the Children's Sleep-Wake Scale<sup/> Sleep Health. 2016 Sep;2(3):198-204. doi: 10.1016/j.sleh.2016.04.001. PubMed 28066802 ↗
  • Zerbini G, Kantermann T, Merrow M. Strategies to decrease social jetlag: Reducing evening blue light advances sleep and melatonin. Eur J Neurosci. 2020 Jun;51(12):2355-2366. doi: 10.1111/ejn.14293. Epub 2018 Dec 13. PubMed 30506899 ↗
  • van der Lely S, Frey S, Garbazza C, Wirz-Justice A, Jenni OG, Steiner R, Wolf S, Cajochen C, Bromundt V, Schmidt C. Blue blocker glasses as a countermeasure for alerting effects of evening light-emitting diode screen exposure in male teenagers. J Adolesc Health. 2015 Jan;56(1):113-9. doi: 10.1016/j.jadohealth.2014.08.002. Epub 2014 Oct 3. PubMed 25287985 ↗
  • Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000 Dec 15;23(8):1043-51. PubMed 11145319 ↗
  • Lebourgeois MK, Wright KP Jr, Lebourgeois HB, Jenni OG. Dissonance Between Parent-Selected Bedtimes and Young Children's Circadian Physiology Influences Nighttime Settling Difficulties. Mind Brain Educ. 2013 Dec;7(4):234-242. doi: 10.1111/mbe.12032. PubMed 24535929 ↗
  • Hartstein LE, Wong SD, Abbas L, Choubai S, Wilson JN, Jablin T, LeBourgeois MK. Creating the Cave: Conducting Circadian Science in Early Childhood. Clocks Sleep. 2023 Feb 20;5(1):85-93. doi: 10.3390/clockssleep5010009. PubMed 36810846 ↗
  • Hartstein LE, Diniz Behn C, Wright KP Jr, Akacem LD, Stowe SR, LeBourgeois MK. Evening Light Intensity and Phase Delay of the Circadian Clock in Early Childhood. J Biol Rhythms. 2023 Feb;38(1):77-86. doi: 10.1177/07487304221134330. Epub 2022 Nov 22. PubMed 36415902 ↗
  • Hartstein LE, Behn CD, Akacem LD, Stack N, Wright KP Jr, LeBourgeois MK. High sensitivity of melatonin suppression response to evening light in preschool-aged children. J Pineal Res. 2022 Mar;72(2):e12780. doi: 10.1111/jpi.12780. Epub 2022 Jan 8. PubMed 34997782 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No identifiable data will be shared. Only de-identified study data will be made available for research purposes.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2030 → Mar 2030, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Feb 6, 2026
StartActual
Jan 29, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Mar 31, 2030was Jul 2030
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
University of Arizona is now Recruiting
Oct 14, 2026
Start date
Jan 15, 2026→Jan 29, 2026 (actual)
Oct 14, 2026
Primary completion
Dec 1, 2029→Dec 31, 2029
Oct 14, 2026
Study completion
Jul 31, 2030→Mar 31, 2030
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    University of Arizona is now Recruiting
    Start date Jan 15, 2026→Jan 29, 2026 (now actual)
    Primary completion Dec 1, 2029→Dec 31, 2029
    Study completion Jul 31, 2030→Mar 31, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07391852
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Jan 29, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Oct 14, 2026

Study contacts

Lauren E Hartstein, PhD
Contact
laurenhartstein@arizona.edu
520-621-1360
Lauren E Hartstein, PhD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion